Management of Mucormycosis

Immediate Actions

• The American College of Physicians and Infectious Diseases specialists recommend starting liposomal amphotericin B at 5-10 mg/kg/day from day one for mucormycosis treatment, while simultaneously arranging urgent surgical consultation 1, 2
• The Infectious Diseases Society of America strongly recommends giving the full dose of liposomal amphotericin B from the first day, avoiding slow dose escalation 1, 2, 3
• For patients with central nervous system (CNS) involvement, the European Society of Clinical Microbiology and Infectious Diseases recommends escalating the dose to 10 mg/kg/day 4, 3
• The American College of Physicians recommends alternative treatment with amphotericin B lipid complex (ABLC) 5 mg/kg/day for non-CNS disease if liposomal amphotericin B is unavailable 5, 3
• The Infectious Diseases Society of America advises against using amphotericin B deoxycholate due to severe nephrotoxicity 6, 7, 4, 3

Surgical Management

• The Surgical Infection Society strongly recommends surgical debridement with clean margins as soon as possible for mucormycosis treatment, with purposes including disease control, obtaining tissue for histopathology, and obtaining specimens for microbiological diagnostics 1, 2, 6
• The American Society of Transplantation recommends surgery as particularly critical for rhino-orbito-cerebral disease, soft tissue infections, and localized pulmonary lesions 5

Reversal of Predisposing Conditions

• The Endocrine Society recommends rapidly correcting hyperglycemia and ketoacidosis, and achieving tight glycemic control immediately for patients with diabetes 3, 6, 7
• The American College of Rheumatology recommends reducing or discontinuing corticosteroids to the minimum necessary dose, and tapering other immunosuppressive agents if feasible 5, 3, 6, 7
• The Infectious Diseases Society of America recommends administering granulocyte colony-stimulating factor (G-CSF) at licensed doses for neutropenic patients 6

Diagnostic Confirmation

• The Clinical and Laboratory Standards Institute recommends obtaining specimens for direct microscopy, histopathology, culture, and molecular methods for species-level identification 7, 4, 3
• The Radiological Society of North America recommends imaging to determine the extent of disease, including CT chest/sinuses/brain depending on clinical presentation 7, 4, 3

Salvage and Second-Line Therapy

• The Infectious Diseases Society of America strongly recommends posaconazole as salvage therapy, with dosing regimens including delayed-release tablets, IV formulation, and oral suspension 1, 2, 6, 4, 5
• The European Society of Clinical Microbiology and Infectious Diseases recommends combination therapy options, including liposomal amphotericin B plus caspofungin, with moderate to marginal strength of evidence 6, 5, 3

Treatment Duration and Monitoring

• The Infectious Diseases Society of America recommends continuing treatment until complete clinical resolution, complete radiological resolution on imaging, and permanent reversal of predisposing factors 7, 4, 5, 3
• The American College of Physicians recommends monitoring laboratory parameters, including serum creatinine, potassium, magnesium, and calcium, and correcting electrolyte disturbances before and during therapy 6, 7, 3

Expected Outcomes

• The Infectious Diseases Society of America reports that mortality remains high despite optimal treatment, with overall mortality ranging from 24-49% 4, 5
• The American College of Physicians notes that survival is significantly better with liposomal amphotericin B (67%) versus conventional amphotericin B (39%) 5

Evidence‑Based Management of Suspected Mucormycosis

Emergency Treatment

• Immediate antifungal therapy with liposomal amphotericin B 5–10 mg/kg/day IV from day 1 (full dose, no test‑dose escalation) together with urgent surgical debridement within 24–48 h is required; delaying treatment beyond 6 days doubles mortality. 8

Diagnostic Imaging

Key Radiologic Signs

• The reversed‑halo sign (ground‑glass opacity surrounded by a consolidation ring) is an early and highly suggestive finding in neutropenic patients. 8
• The hypodense sign on T1‑weighted MRI (central hypodensity indicating necrosis from vascular obstruction) strongly suggests mucormycosis. 8
• The vascular‑occlusion sign on CT angiography (interrupted vessel at the lesion border) is characteristic of invasive disease. 9
• Contiguous spread showing invasion of adjacent structures on imaging indicates aggressive disease extension. 10

Tissue Diagnosis

• Obtaining tissue specimens via surgical debridement or biopsy within 24 h serves three critical purposes: rapid disease control, histopathologic confirmation (irregular, non‑septate hyphae branching at right angles), and microbiologic identification. 8

First‑Line Antifungal Therapy

• Liposomal amphotericin B 5–10 mg/kg/day IV from day 1, administered at the full recommended dose without gradual escalation, is the primary recommendation. 8
• Avoid slow dose escalation; this practice significantly worsens outcomes. 8

Alternative First‑Line Options (when liposomal amphotericin B unavailable)

• Isavuconazole IV 200 mg three times daily on days 1–2, then 200 mg once daily from day 3 onward. 8
• Posaconazole IV 300 mg twice daily on day 1, then 300 mg once daily from day 2 onward. 8

Salvage Therapy

• Posaconazole is the strongly recommended salvage agent for disease progression or amphotericin B intolerance.
  
  • Dosing options:
    
    • Delayed‑release tablets 300 mg twice daily on day 1, then 300 mg once daily.
    • IV formulation 300 mg twice daily on day 1, then 300 mg once daily.
    • Oral suspension 200 mg four times daily. 8
• Posaconazole salvage therapy achieves response rates of 60–80 %, especially when combined with surgical debridement. 8